Bio-Path Holdings implemented an operational pause in June 2025 following unsuccessful capital raises, resulting in widespread employee furloughs and a halt to clinical trials. The company is actively negotiating with creditors and forming a Scientific Advisory Board to support potential restructuring and trial resumption efforts. Its proprietary drug candidates targeting acute myeloid leukemia (AML) and solid tumors provide a scientific moat but require financing and milestone progress to unlock value. Liquidity remains critically constrained as current liabilities vastly exceed assets, creating material uncertainty about Bio-Path’s viability absent successful fundraising or partnerships.